Prognostic Impact of pT Stage and Peritoneal Invasion in Locally Advanced Colon Cancer
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Rosello, S
- Cervantes, A
Grupos
Abstract
BACKGROUND: TNM stage has been identified as an independent variable for local recurrence and survival after colon cancer resection. It is still unclear whether peritoneal invasion (pT4a) is a risk factor for adverse oncologic outcome or whether these patients have better results compared with contiguous organs infiltration (pT4b), independent from nodal status (pN). OBJECTIVE: The purpose of this study was to analyze whether peritoneal invasion is an independent risk factor for worse oncologic outcome after curative colon cancer resection. DESIGN: This was a retrospective analysis with multivariate regression of a prospective database, according to Strengthening the Reporting of Observational Studies in Epidemiology Statement. SETTINGS: The study was conducted in a specialized colorectal unit of a tertiary hospital. PATIENTS: A consecutive series of pT3-pT4a-pT4b patients with colon cancer who underwent curative surgery (1993-2010) were included, and patients with metastasis were excluded. MAIN OUTCOME MEASURES: A multivariate Cox regression analysis was performed to assess independent risk factors for 5-year local recurrence, peritoneal carcinomatosis-like recurrence, disease-free survival, and cancer-specific survival. RESULTS: A total of 1010 patients were analyzed (79.3% pT3, 9.9% pT4a, and 10.8% pT4b). At diagnosis, 22.0% had obstructive symptoms, and 10.5% had bowel perforation. A total of 72.2% of the surgeries were elective, and in 15.6% en bloc resection of contiguous organs was performed. Median follow-up was 62 months (38-100 mo). For the whole group, 5-year actuarial rates were 8.8% for local recurrence, 2.5% for peritoneal carcinomatosis, 75.5% for disease-free survival, and 81.8% for cancer-specific survival. At multivariate analysis, pT4a stage was an independent risk factor for local recurrence (p = 0.002; HR = 3.1), peritoneal carcinomatosis (p = 0.02; HR = 4.9), worse diseasefree survival (p = 0.002; HR = 1.9), and cancer-specific survival (p = 0.001; HR = 2.2). When considering only the 566 patients with >= 12 nodes identified, T stage was still associated with higher local recurrence (p = 0.04) and carcinomatosis rate (p = 0.04), as well as worse diseasefree (p = 0.009) and cancer-specific survival (p = 0.014). LIMITATIONS: This was a retrospective, single-center study. CONCLUSIONS: pT4a stage is an independent risk factor for worse oncologic outcome after curative colon cancer resection compared with pT3 and pT4b stages. The current pT4a-pT4b classification should be reconsidered. Of note, even in pT4a patients, 5-year carcinomatosis rate does not exceed 6%. See Video Abstract at http://links.lww.com/DCR/A926.
Datos de la publicación
- ISSN/ISSNe:
- 0012-3706, 1530-0358
- Tipo:
- Article
- Páginas:
- 684-693
- Factor de Impacto:
- 1,550 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
DISEASES OF THE COLON & RECTUM LIPPINCOTT WILLIAMS & WILKINS
Citas Recibidas en Web of Science: 22
Documentos
- No hay documentos
Filiaciones
Keywords
- Carcinomatosis; Colon cancer; Locally advanced colon cancer; Prognosis; Survival; T stage; Tumor-node-metastasis
Proyectos asociados
WIBEC. WIRELESS IN-BODY ENVIRONMENT COMMUNICATIONS.
Investigador Principal: VICENTE PONS BELTRÁN
675353 . COMISION EUROPEA . 2016
MODELOS DE HÍGADO AISLADO PERFUNDIDO PARA EL RESCATE DE ÓRGANOS Y TRASLACIÓN DE LA TERAPIA GÉNICA EN EL TRASPLANTE: ESCENARIOS HUMANO "EX VIVO" Y PORCINO "IN VIVO"
Investigador Principal: RAFAEL LÓPEZ ANDÚJAR
2017_0270_CRC_LOPEZ . FUNDACION MUTUA MADRILEÑA . 2017
Ileostomía vistual combinada con endoscopia postoperatoria ebn cáncer de recto con escisión total mesorrectal. ¿podemos evitar estomas innecesarios? estudio prospectivo observacional multicénctrico.
Investigador Principal: BLAS FLOR LORENTE
PI17/00863 . INSTITUTO DE SALUD CARLOS III . 2018
"TIMing Evaluation of Stoma closure” Cierre precoz vs tardío del estoma derivativo tras cirugía de cáncer de recto.
Investigador Principal: MATTEO FRASSON
2018_0078_CRC_FRASSON . ASOCIACIÓN ESPAÑOLA DE COLOPROCTOLOGÍA (AECP) . 2018
Terápia génica no-viral con 1L 10 para el tratamiento de la enfermedad inflamatoria intestinal. Estudio preliminar con piezas de cólon humano ex vivo.
Investigador Principal: MATTEO FRASSON
PI18/01658 . INSTITUTO DE SALUD CARLOS III . 2019
ESTUDIO PILOTO DEL TRATAMIENTO DEL LIQUEN ESCLEROSO VULVAR MEDIANTE TEJIDO ADIPOSO ASOCIADO A PLASMA RICO EN PLAQUETAS AUTÓLOGO.
Investigador Principal: PATRICIA GUTIERREZ ONTALVILLA
LIQUENIA . 2017
INDIVIDUALIZED PERIOPERATIVE HEMODYNAMIC GOAL-DIRECTED THERAPY IN MAJOR ABDOMINAL SURGERY (IPEGASUS-TRIAL).
Investigador Principal: ÓSCAR DÍAZ CAMBRONERO
IPEGASUS . 2017
MU OPIOID RECEPTOR 1 (MOR-1) EXPRESSION IN COLORECTAL CANCER AND DISEASE-FREE SURVIVAL RELATIONSHIP (MOROCCO). FIVE-YEAR FOLLOW-UP.
Investigador Principal: ÓSCAR DÍAZ CAMBRONERO
ODC-MOR-2018-01
ESTUDIO PROSPECTIVO, ALEATORIZADO, DOBLE-CIEGO, INTERNACIONAL Y MULTICÉNTRICO SOBRE LA SEGURIDAD Y LA EFICACIA DE LA SOLUCIÓN 6% HIDROXIETIL ALMIDÓN (HYDROXYETHYL STARCH) (HES) COMPARADA CON UNA SOLUCIÓN ELECTROLÍTICA EN PACIENTES SOMETIDOS A CIRUGÍA ABDOMINAL: ESTUDIO PHOENICS.
Investigador Principal: ÓSCAR DÍAZ CAMBRONERO
HC-G-H-1504 (PHOENICS) . 2018
MANAGEMENT OF ACUTE SEVERE ULCERATIVE COLITIS (MASC).
Investigador Principal: MATTEO FRASSON
MFR-CIC-2018-01 . 2019
ESTUDIO ALEATORIZADO MULTICÉNTRICO EN FASE III DE RADIOTERAPIA DE CORTA DURACIÓN SEGUIDA DE QUIMIOTERAPIA PREOPERATORIA DE LARGA DURACIÓN Y CIRUGÍA EN EL CÁNCER RECTAL PRIMARIO DE ALTO RIESGO EN COMPARACIÓN CON QUIMIORRADIOTERAPIA CONVENCIONAL Y CIRUGÍA Y OPTIMA QUIMIOTERAPIA ADYUVANTE.
Investigador Principal: JORGE APARICIO URTASUN
RAPIDO
ENSAYO CLÍNICO MULTICÉNTRICO ALEATORIZADO EN PACIENTES CON CÁNCER COLO-RECTAL CON METÁSTASIS IRRESECABLES. IMPACTO DE LA RESECCIÓN TUMORAL VS QUIMIOTERAPIA SOLA SOBRE LA SUPERVIVENCIA.
Investigador Principal: FRANCISCO JAVIER VAQUE URBANEJA
01CCRE-IV
ESTUDIO OBSERVACIONAL PARA EVALUAR LA ESTRATEGIA DE USO DE LAS TERAPIAS DIRIGIDAS, EN CÁNCER DE COLON METASTÁSICO.
Investigador Principal: JORGE APARICIO URTASUN
GEM-BEV-2013-01 . 2015
COMPLICACIONES DE HERIDA QUIRÚRGICA EN PACIENTES INTERVENIDOS DE EVENTRACIÓN. ESTUDIO PILOTO COMPARATIVO DE APÓSITO QUIRÚRGICO CONVENCIONAL FRENTE A TERAPIA DE PRESIÓN NEGATIVA DE UN SOLO USO.
Investigador Principal: ASCENSIÓN FRANCO BERNAL
PICO
UTILIDAD DE UNA MALLA SUPRAAPONEURÓTICA COMO PROFILAXIS DE LA EVENTRACIÓN DE LINEA MEDIA TRAS RESECCIÓN ONCOLOGICA COLORRECTAL. ESTUDIO PROSPECTIVO ALEATORIZADO MONOCÉNTRICO.
Investigador Principal: MATTEO FRASSON
PEACE . 2016
MINIMALLY INVASIVE RIGHT COLECTOMY ANASTOMOSIS STUDY (MIRCAST).
Investigador Principal: MATTEO FRASSON
MIRCAST . 2019
Cita
Baguena G,Pellino G,Frasson M,Rosello S,Cervantes A,Garcia A,Giner F,Garcia E. Prognostic Impact of pT Stage and Peritoneal Invasion in Locally Advanced Colon Cancer. Dis Colon Rectum. 2019. 62. (6):p. 684-693. IF:3,991. (1).